Breaking News Instant updates and real-time market news.

SELB

Selecta Biosciences

$9.25

-4.12 (-30.82%)

, HZNP

Horizon Pharma

$18.49

-0.76 (-3.95%)

14:29
10/23/18
10/23
14:29
10/23/18
14:29

Selecta SEL-212 data 'very competitive to Krystexxa mono/combo therapy, says Stifel

Stifel analyst Derek Archila views Selecta Biosciences (SELB) SEL-212 Phase 2 data in chronic severe gout as positive and thinks it represents a "very competitive" emerging profile relative to the incumbent brand, Horizon Pharma's (HZNP) Krystexxa. The analyst comes away positive with the fact SEL-212's projected response rate remains competitive on a modified intent-to-treat basis, SVP-Rapamycin was tolerable out to five months of dosing, and SEL-212's rate of gout flares was lower than Krystexxa alone and Krystexxa+methotrexate early on. Archila remains positive on the stock and believes SEL-212 could offer an improvement to the current standard of care for chronic severe gout. Further, Archila does not believe shares fully reflect the program's commercial potential and reiterates a Buy rating on Selecta's shares.

SELB

Selecta Biosciences

$9.25

-4.12 (-30.82%)

HZNP

Horizon Pharma

$18.49

-0.76 (-3.95%)

  • 23

    Oct

  • 23

    Oct

  • 07

    Nov

  • 27

    Nov

SELB Selecta Biosciences
$9.25

-4.12 (-30.82%)

10/23/18
COWN
10/23/18
NO CHANGE
Target $25
COWN
Outperform
Cowen says Horizon positive news about Krystexxa competitor outweighs 340(B)
After Selecta Biosciences (SELB) released "disappointing" data from its potential competitive program to Horizon Pharma's (HZNP) Krystexxa, Cowen analyst Ken Cacciatore said the news "virtually eliminates [SEL-212] as a threat" and far outweighs the modestly negative potential 340(B) timing change. While HHS is proposing to change the date on which 340(B) pricing would come into effect from July 1, 2019, to January 1, 2019, Cacciatore called this news "largely irrelevant" since his model for Horizon already assumed adjustments to the program beginning in July 2019, he added. He contends that the net of these two disclosures should be viewed "much more positively than negatively" and would be adding to Horizon positions, Cacciatore tells investors. He keeps an Outperform rating on Horizon Pharma shares with a $25 price target.
10/23/18
ADAM
10/23/18
NO CHANGE
ADAM
Selecta Biosciences weakness a buying opportunity, says Canaccord
10/23/18
MZHO
10/23/18
NO CHANGE
Target $30
MZHO
Buy
Selecta stock reaction to SEL-212 data 'overly negative,' says Mizuho
Mizuho analyst Difei Yang believes the market reaction to Selecta Biosciences' (SELB) Phase 2 data on SEL-212 is "overly negative," stating that she believe it is likely acceptable to the FDA to proceed into Phase 3. While not as good as she had hoped for, she still sees the data remaining superior to standalone Krystexxa, marketed by Horizon Pharma (HZNP), "especially considering stringent stopping rules and evaluation criteria in the trial," Yang tells investors. She keeps a Buy rating and $30 price target on Selecta shares.
10/23/18
JANY
10/23/18
NO CHANGE
JANY
Buy
Selecta Biosciences weakness an 'overreaction,' says Janney Montgomery Scott
HZNP Horizon Pharma
$18.49

-0.76 (-3.95%)

10/05/18
JMPS
10/05/18
NO CHANGE
Target $22
JMPS
Outperform
Horizon's teprotumumab data 'a game-changer,' says JMP Securities
JMP Securities analyst Donald Ellis called Horizon Pharma's long-term, 72-week data on teprotumumab "a game-changer" that he believes will position the drug as a first-line therapy for treating thyroid eye disease, or TED. Ellis, who foresees a potential filing for teprotumumab in mid-2019 and potential approval in early 2020, keeps an Outperform rating and $22 price target on Horizon Pharma shares.
10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).

TODAY'S FREE FLY STORIES

APYX

Apyx Medical

$7.93

0.005 (0.06%)

13:25
03/18/19
03/18
13:25
03/18/19
13:25
Conference/Events
Apyx Medical management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

T

AT&T

$30.77

0.09 (0.29%)

13:24
03/18/19
03/18
13:24
03/18/19
13:24
Periodicals
Kevin Tsujihara ousted as Warner Bros. CEO, CNBC reports »

Kevin Tsujihara has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 24

    Apr

  • 26

    Apr

  • 20

    May

CXP

Columbia Property

$21.99

-0.13 (-0.59%)

13:21
03/18/19
03/18
13:21
03/18/19
13:21
Conference/Events
Columbia Property management to meet with JMP Securities »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

BSX

Boston Scientific

$37.77

-2.38 (-5.93%)

13:20
03/18/19
03/18
13:20
03/18/19
13:20
Options
Quarter million dollar block of calls sold to open in Boston Scientific »

Quarter million dollar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

  • 28

    May

MIK

Michaels

$11.72

0.04 (0.34%)

, DSW

DSW

$25.05

-0.34 (-1.34%)

13:19
03/18/19
03/18
13:19
03/18/19
13:19
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MIK

Michaels

$11.72

0.04 (0.34%)

DSW

DSW

$25.05

-0.34 (-1.34%)

HDS

HD Supply

$42.88

-0.12 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

REGN

Regeneron

$408.15

-6.03 (-1.46%)

, DERM

Dermira

$12.46

5.63 (82.43%)

13:17
03/18/19
03/18
13:17
03/18/19
13:17
On The Fly
Dermira rises, Regeneron slips on eczema treatment study results »

Shares of Dermira (DERM)…

REGN

Regeneron

$408.15

-6.03 (-1.46%)

DERM

Dermira

$12.46

5.63 (82.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 13

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
03/18/19
03/18
13:17
03/18/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
03/18/19
03/18
13:16
03/18/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBCP

Home Bancorp

$36.50

0.59 (1.64%)

13:14
03/18/19
03/18
13:14
03/18/19
13:14
Hot Stocks
Home Bancorp CEO John Bordelon sells over $232K shares of company stock »

Home Bancorp CEO John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELAN

Elanco

$31.38

0.69 (2.25%)

13:14
03/18/19
03/18
13:14
03/18/19
13:14
Periodicals
Elanco tells Bloomberg CEO not planing to sell shares at lockup »

Elanco CEO Jeffrey…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

APEN

Apollo Endosurgery

$3.29

-0.06 (-1.79%)

13:13
03/18/19
03/18
13:13
03/18/19
13:13
Recommendations
Apollo Endosurgery analyst commentary  »

Piper says Apollo's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 18

    May

  • 28

    May

QQQ

Invesco QQQ Trust

$178.07

0.1542 (0.09%)

13:10
03/18/19
03/18
13:10
03/18/19
13:10
Options
50K Invesco QQQ Jun 188 - 192 call spreads sold at 95c »

50K Invesco QQQ Jun 188 -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARS

Cars.com

$22.75

0.04 (0.18%)

13:05
03/18/19
03/18
13:05
03/18/19
13:05
Options
Cars.com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:05
03/18/19
03/18
13:05
03/18/19
13:05
General news
FOMC Forecast revisions »

FOMC Forecast revisions…

AIR

AAR Corp.

$35.01

0.92 (2.70%)

13:01
03/18/19
03/18
13:01
03/18/19
13:01
Hot Stocks
AAR awarded $10.8M order from USAF to produce cargo pallets »

AAR has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

MYL

Mylan

$28.32

0.24 (0.85%)

12:51
03/18/19
03/18
12:51
03/18/19
12:51
Hot Stocks
Mylan Institutional LLC initiates voluntary recall of Levoleucovorin Injection »

Mylan Institutional LLC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTS

Ladenburg Thalmann

$2.99

0.03 (1.01%)

12:50
03/18/19
03/18
12:50
03/18/19
12:50
Recommendations
Ladenburg Thalmann analyst commentary at Barrington »

Ladenburg Thalmann price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$44.88

-0.19 (-0.42%)

12:49
03/18/19
03/18
12:49
03/18/19
12:49
Periodicals
Sanofi says working on plan to find new CEO, Reuters reports »

Sanofi is working on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 28

    Apr

ATVI

Activision Blizzard

, SUI

Sun Communities

12:46
03/18/19
03/18
12:46
03/18/19
12:46
On The Fly
Fly Insider: Activision, Zebra among week's notable insider transactions »

Welcome to "Fly Insider,"…

ATVI

Activision Blizzard

SUI

Sun Communities

VRTX

Vertex

ESGR

Enstar Group

PBF

PBF Energy

OPK

Opko Health

$2.48

-0.035 (-1.39%)

CVS

CVS Health

FANG

Diamondback Energy

D

Dominion

SIX

Six Flags

BCO

Brink's

BK

BNY Mellon

PLNT

Planet Fitness

TNDM

TNDM

TTD

Trade Desk

AMH

American Homes 4 Rent

ZBRA

Zebra Technologies

ANSS

Ansys

IBP`

IBP Inc

COST

Costco

ZGNX

Zogenix

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

  • 25

    Mar

  • 25

    Mar

  • 25

    Mar

  • 02

    Apr

  • 04

    Apr

  • 09

    Apr

  • 10

    Apr

  • 16

    Apr

  • 16

    Apr

  • 17

    Apr

  • 25

    Apr

  • 01

    May

  • 07

    May

  • 09

    May

  • 28

    May

  • 30

    May

ACA

Arcosa

$31.98

0.03 (0.09%)

12:46
03/18/19
03/18
12:46
03/18/19
12:46
Initiation
Arcosa initiated at Stephens »

Arcosa initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 19

    Mar

SEDG

SolarEdge

$39.40

-0.57 (-1.43%)

12:45
03/18/19
03/18
12:45
03/18/19
12:45
Recommendations
SolarEdge analyst commentary at Vertical Group »

SolarEdge lost second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 20

    Mar

  • 21

    Mar

APHA

Aphria

$10.22

0.62 (6.46%)

12:45
03/18/19
03/18
12:45
03/18/19
12:45
Options
Aphria call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$202.24

3.97 (2.00%)

, SPGI

S&P Global

$205.03

1.91 (0.94%)

12:43
03/18/19
03/18
12:43
03/18/19
12:43
Hot Stocks
GSAM acquires S&P's Investment Advsisory Services; terms not disclosed »

Goldman Sachs Asset…

GS

Goldman Sachs

$202.24

3.97 (2.00%)

SPGI

S&P Global

$205.03

1.91 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$187.25

1.05 (0.56%)

12:36
03/18/19
03/18
12:36
03/18/19
12:36
Periodicals
Apple launches sixth developer beta of iOS 12.2, MacRumors reports »

Apple today plans to seed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMS

Scientific Games

$22.26

-0.67 (-2.92%)

12:35
03/18/19
03/18
12:35
03/18/19
12:35
Options
Scientific Games put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.